About the Event
Following the success of the 2016 conference in London, we present the Immuno-Oncology Summit Europe 2017. Once again our venue is in central London, an ideal meeting place for international academic and industry experts.
Attendees can now experience an entire week of updates and discussion. In Novel Approaches for Cancer we will focus on T cells and their receptors including chimeric antigen receptor (CAR-T) technology, bispecifics, preclinical models, and targets and lead selection. Immunomodulatory Approaches will look at advances in checkpoint inhibitors, agonistic receptor engagement, NK, macrophage and dendritic cell activation, Fc-engineering technologies, cytokine-based therapies and oncolytic vaccines. Combination Immunotherapy will examine design of immunotherapy combinations, combination strategies and provide preclinical and clinical updates.
"Very stimulatory meeting in an exciting field. Great mix of complementary presentations."
Kerry Chester, Ph.D., Professor, UCL Cancer Institute
"I believe you managed to collate an excellent mix of speakers spanning the most critical aspects of immune oncology, providing an informal forum for discussions between leaders in the field and new investigators coming from both academia and industry."
Björn Frendéus, Ph.D., Chief Scientific Officer, BioInvent International AB
"The content of the meeting was highly relevant and up to date."
Khaterech Ahmadi, Executive Director, MSD-Merck
"The meeting was ideal in terms of size and content. I really enjoyed the conference. It was very insightful and great quality of research was presented."
Sujiet Puthenveetil, Ph.D., Principal Scientist, Medicinal Chemistry, Pfizer, Inc.